ReviewAntonie van Leeuwenhoek2026
Quorum sensing disruption in Enterobacter spp.: unlocking new therapeutic pathways against multidrug-resistant infections.
Review in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quorum-quenching enzymes as next-generation antibiofilm therapeutics: mechanisms, applications, and future perspectives.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterobacter spp., members of the ESKAPE group of pathogens, are increasingly recognized for their involvement in nosocomial infections and remarkable adaptability, particularly in hospital settings. This review highlights the intricate quorum-sensing (QS) systems in Enterobacter species, emphasizing both canonical and non-canonical pathways, including the acyl-homoserine lactone-mediated AI-1 system, LuxS-dependent AI-2 systems, and the solo LuxR system. QS systems regulate critical bacterial behaviors, including biofilm formation, antibiotic resistance, and virulence gene expression. Additionally, the role of quorum quenching (QQ) as a potentially effective anti-virulence strategy is also discussed, with a focus on enzymatic and natural-product-based approaches that disrupt bacterial communication. Enzymes, such as lactonases, and synthetic or plant-derived QS inhibitors have been explored for their ability to attenuate pathogenic traits without exerting the selective pressure that typically drives antimicrobial resistance. Despite significant advances in elucidating QS and QQ processes in Enterobacter spp., notable limitations remain in the molecular understanding of species-specific QS control, particularly regarding the AI-3 signalling pathway and its functional significance. This extensive study seeks to promote future investigations into quorum-sensing disruption as a novel anti-virulence approach and its possible therapeutic application.
Indexed as
Identifiers
41903029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.